natgillin/translations-raw huggingface dataset:
cyclosporin, tacrolimus, and sirolimus (medicines to decrease the effects of body's immune system)
ciklosporin, takrolimus i sirolimus (lijekovi za sniženje učinaka imunološkog sustava tijela)
Cyclosporin, tacrolimus, sirolimus
Ciklosporin, takrolimus, sirolimus
cyclosporin, tacrolimus, sirolimus (used to prevent organ rejection (to suppress the immune system))
ciklosporin, takrolimus, sirolimus (primjenjuju se za sprječavanje odbacivanja organa (za supresiju imunološkog sustava))
cyclosporin, used during and after organ transplants oral contraceptives, used to prevent pregnancy.
ciklosporin, koristi se tijekom i nakon presađivanja organa oralne kontraceptive, koriste se u svrhu sprječavanja trudnoće.
Cyclosporin:  expected Rapamycin:  expected Tacrolimus:  expected
Ciklosporin: očekuje se  Rapamicin: očekuje se  Takrolimus: očekuje se 
Cyclosporine
ciklosporin
Cyclosporine 400 mg single dose (daclatasvir 60 mg once daily)
ciklosporin u pojedinačnoj dozi od 400 mg (daklatazvir 60 mg jedanput na dan)
Cyclosporine A (Indinavir/ritonavir 800/100 BID)
Ciklosporin A (indinavir/ritonavir 800/100 BID)
Cyclosporine A dose adjustments should be made according to measured cyclosporine A trough blood levels.
Dozu ciklosporina A treba prilagoditi izmjerenim vrijednostima ciklosporina A u krvi.
Cyclosporine A, tacrolimus - medicines that affect your immune system.
Ciklosporin A, takrolimus - lijekovi koji utječu na imunološki sustav.
Cyclosporine A: co-administration of STAYVEER and cyclosporine A (a calcineurin inhibitor) is contraindicated (see section 4.3).
Ciklosporin A: istodobna primjena STAYVEERA i ciklosporina A (inhibitor kalcineurina) kontraindicirana je (vidjeti dio 4.3).
Cyclosporine A: co-administration of Tracleer and cyclosporine A (a calcineurin inhibitor) is contraindicated (see section 4.3).
Ciklosporin A: istodobna primjena Tracleera i ciklosporina A (inhibitor kalcineurina) kontraindicirana je (vidjeti dio 4.3).
Cyclosporine A: Concomitant treatment with cyclosporine A 100 mg b.i.d., a combined CYP3A4 and OATP inhibitor, did not alter the steady-state exposure to macitentan and its active metabolite to a clinically relevant extent.
Ciklosporin A: Istovremena primjena ciklosporina A 100 mg dva puta dnevno, kombiniranog inhibitora CYP3A4 i OATP, nije promijenila izloženost macitentanu i njegovom aktivnom metabolitu u stanju dinamičke ravnoteže do klinički relevantne mjere.
cyclosporine and tacrolimus (used to treat transplant rejection), digoxin (used to treat irregular heart rate), and metformin (used to control your blood sugar) proton pump inhibitors (used to treat heartburn)
ciklosporin i takrolimus (koriste se u liječenju protiv odbacivanja presadaka), digoksin (koristi se za liječenje nepravilnog srčanog ritma) i metformin (koristi se za kontrolu šećera u krvi) inhibitore protonske pumpe (koriste se za liječenje žgaravice)
cyclosporine AUC ↑ 168%
ciklosporin AUC ↑ 168
cyclosporine blood
te nuspojava povezanih s
cyclosporine Cmax ↑ 101%
ciklosporin Cmax ↑ 101
cyclosporine – a medicine used to suppress the immune system for example after organ transplantations ritonavir, saquinavir – medicines used to treat HIV
ciklosporin – lijek koji se primjenjuje za potiskivanje rada imunološkog sustava, na primjer nakon presađivanja organa ritonavir, sakvinavir – lijekovi koji se primjenjuju u liječenju infekcije virusom HIV
cyclosporine)
ciklosporin)
cyclosporine*
ciklosporin
cyclosporine, sirolimus and tacrolimus – medicines that suppress the “self-defense” ability of the body and fight infections and are commonly used to prevent the rejection of transplanted organs such as the liver, heart and kidney;
ciklosporin, sirolimus i takrolimus – lijekovi koji potiskuju sposobnost tijela za „samoobranu“ i borbu protiv infekcija te se obično koriste za sprječavanje odbacivanja presađenih organa kao što su jetra, srce i bubreg;
cyclosporine, sirolimus, tacrolimus
ciklosporin, sirolimus, takrolimus
cyclosporine, sirolimus, tacrolimus (immunosuppressants)
ciklosporin, sirolimus, takrolimus (imunosupresivi)
cyclosporine, sirolimus, tacrolimus (used before or after transplant surgery)
ciklosporin, sirolimus, takrolimus (koriste se prije ili nakon transplantacijskog kirurškog zahvata)
cyclosporine, sirolimus, tacrolimus – used to suppress the immune system methotrexate – used to treat cancer, rheumatoid arthritis and psoriasis
ciklosporin, sirolimus, takrolimus – koriste se za supresiju imunološkog sustava metotreksat – koristi se za liječenje raka, reumatoidnog artritisa i psorijaze
Cyclosporine, tacrolimus, everolimus Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A4 and as a result is expected to increase the plasma concentrations of cyclosporine, tacrolimus or everolimus.
Ciklosporin, takrolimus, everolimus Ritonavir doziran kao farmakokinetički pojačivač ili kao antiretrovirusni lijek inhibira CYP3A4, zbog čega se očekuje povećanje koncentracije ciklosporina, takrolimusa i everolimusa u plazmi.
cyclosporine, tacrolimus, sirolimus (all three used to prevent rejections of liver, kidney and heart transplants);
ciklosporin, takrolimus, sirolimus (sva tri lijeka koriste se za sprečavanje odbacivanja presađenih organa – jetre, bubrega i srca);
cyclosporine, tacrolimus, sirolimus, everolimus (immunosuppressants),
ciklosporin, takrolimus, sirolimus, everolimus (imunosupresivi),
cyclosporine-related side
primjenom ciklosporina.
Cymbalta 30 mg hard gastro-resistant capsules
Cymbalta 30 mg tvrde želučanootporne kapsule
Cymbalta 30 mg hard gastro-resistant capsules Cymbalta 60 mg hard gastro-resistant capsules Duloxetine (as hydrochloride)
Cymbalta 30 mg tvrde želučanootporne kapsule Cymbalta 60 mg tvrde želučanootporne kapsule duloksetin (u obliku duloksetinklorida)
Cymbalta 30 mg is available in packs of 7, 28 and 98 capsules.
Cymbalta 30 mg dostupna je u pakiranjima koja sadrže 7, 28 i 98 kapsula.
Cymbalta 30 mg is available in packs of 7, 28 and 98 capsules.
Cymbalta 30 mg dostupna je u pakiranjima od 7, 28 i 98 kapsula.
Cymbalta 60 mg hard gastro-resistant capsules
Cymbalta 60 mg tvrde želučanootporne kapsule
Cymbalta 60 mg is available in packs of 28, 56, 84, 98, 100 (Each pack contains 5 cartons of 20 capsules) and 500 capsules (Each pack contains 25 cartons of 20 capsules).
Cymbalta 60 mg dostupna je u pakiranjima koja sadrže 28, 56, 84, 98, 100 (jedno pakiranje sadrži 5 kutija s 20 kapsula) i 500 kapsula (jedno pakiranje sadrži 25 kutija s 20 kapsula).
Cymbalta 60 mg is available in packs of 28, 56, 84, 98, 100 and 500 capsules.
Cymbalta 60 mg dostupna je u pakiranjima od 28, 56, 84, 98, 100 i 500 kapsula.
Cymbalta 60 mg to 120 mg once daily demonstrated statistically significant superiority compared to placebo (p<0.001) on the prevention of relapse, as measured by time to relapse.
Cymbalta u dozi od 60 do 120 mg jednom dnevno bila je statistički značajno superiornija u odnosu na placebo (p<0,001) u prevenciji relapsa, mjereno vremenom do pojave relapsa.
Cymbalta contains the active substance duloxetine.
Cymbalta sadrži djelatnu tvar duloksetin.
Cymbalta is indicated in adults.
Cymbalta je indicirana kod odraslih.
Cymbalta is used in adults to treat:
Cymbalta se primjenjuje u odraslih za liječenje:
Cymbalta may cause effects that you may not be aware of, such as increases in liver enzymes or blood levels of potassium, creatine phosphokinase, sugar, or cholesterol
Cymbalta može uzrokovati nuspojave kojih možda i niste svjesni, poput povišenih vrijednosti jetrenih enzima ili povišene koncentracije kalija, kreatin fosfokinaze, šećera ili kolesterola u krvi
Cymbalta may make you feel sleepy or dizzy.
Cymbalta može izazvati pospanost ili omaglicu.
Cymbalta must not be used in patients with liver disease resulting in hepatic impairment (see sections 4.3 and 5.2).
Cymbalta se ne smije davati bolesnicima s bolešću jetre čija je posljedica oštećenje jetrene funkcije (vidjeti dijelove 4.3 i 5.2).
Cymbalta should not be used in combination with fluvoxamine, ciprofloxacin or enoxacin (i.e. potent CYP1A2 inhibitors) since the combination results in elevated plasma concentrations of duloxetine (see section 4.5).
Cymbalta se ne smije primjenjivati u kombinaciji s fluvoksaminom, ciprofloksacinom ili enoksacinom (tj. potentnim inhibitorima CYP1A2) jer se pri toj kombinaciji povećava koncentracija duloksetina u plazmi (vidjeti dio 4.5).
Cymbalta should not be used in the treatment of children and adolescents under the age of 18 years.
Cymbalta se ne smije primjenjivati u liječenju djece i adolescenata mlađih od 18 godina.
CYP 3A4 inducer effect of rifampicin.
Mogući je izraženiji učinak na
CYP 3A4 inducers
Induktori CYP3A4
CYP 3A4 inhibition and induction by tipranavir/r
CYP 3A4 inhibicija i indukcija
CYP 3A4 inhibition by tipranavir/r
CYP 3A4 inhibicija putem
CYP dependent metabolites account for approximately 43% of the total excreted radioactivity, while non- CYP dependent hydrolytic metabolites account for 25%, and excretion of unchanged pomalidomide accounted for 10% (2% in urine and 8% in faeces).
Metaboliti ovisni o CYP čine približno 43% ukupno izlučene radioaktivnosti, metaboliti koji ne ovise o CYP čine 25%, dok je izlučivanje neizmijenjenog pomalidomida činilo 10% (2% u mokraći i 8% u stolici).
CYP inducers (see section 4.3).
P-gp-a i CYP-a (vidjeti dio 4.3).
CYP isoforms 2E1, 1A2, 2B6, 2C8, and 2C19 are involved to a lesser extent and isoforms 2D6 and 2C9 are not involved in the metabolism of lomitapide.
Izoforme CYP-a 2E1, 1A2, 2B6, 2C8 i 2C19 uključene su u manjem opsegu a izoforme 2D6 i 2C9 nisu uključene u metabolizam lomitapida.
CYP1A, 2C8, 2C9, 2D6 and 3A4) inhibitors.
CYP1A, 2C8, 2C9, 2D6 i 3A4).
CYP1A1 catalyses the formation of riociguat’s main metabolite in liver and lungs and is known to be inducible by polycyclic aromatic hydrocarbons, which, for example, are present in cigarette smoke.
CYP1A1 katalizira stvaranje glavnog metabolita riocigvata u jetri i plućima, a poznato je da ga induciraju policiklički aromatski ugljikovodici, koji su prisutni, na primjer, u duhanskom dimu.
CYP1A2 and CYP3A4 are enzymes identified to play a role in the metabolism of tasimelteon.
CYP1A2 i CYP3A4 su enzimi za koje je utvrđeno da imaju ulogu u metabolizmu tazimelteona.
CYP1A2 and P450-CYP2D6 contribute to the formation of the N-desmethyl and 2-hydroxymethyl metabolites, both exhibited significantly less in vivo pharmacological activity than olanzapine in animal studies.
P450-CYP2D6 doprinose stvaranju N-desmetil i 2-hidroksimetil metabolita te u ispitivanjima na životinjama oba pokazuju značajno manje in vivo farmakološko djelovanje od olanzapina.
CYP1A2 inducers such as carbamazepine and rifampicin may give rise to reduced plasma concentrations of melatonin.
Induktori CYP1A2, kao što su karbamazepin i rifampicin, mogu prouzročiti sniženje koncentracije melatonina u plazmi.
CYP1A2 inhibitors such as quinolones may give rise to increased melatonin exposure.
Inhibitori CYP1A2, poput kinolona, mogu dovesti do povećane ekspozicije melatoninu.
CYP2A6 and
CYP2A6 i CYP3A4
CYP2B6 catalyzes the metabolic conversion of cyclophosphamide to its active form 4-hydroxycyclophosphamide (4-OHCP) and co-administration of thiotepa may therefore lead to decreased concentrations of the active 4-OHCP.
CYP2B6 katalizira metaboličku pretvorbu ciklofosfamida u njegov aktivni oblik 4- hidroksiciklofosfamid (4-OHCP) i stoga istodobna upotreba s tiotepom može dovesti do smanjenja koncentracije aktivnog 4-OCHP.
CYP2B6 inducers, inhibitors and substrates
CYP2B6 induktori, inhibitori i supstrati
CYP2B6 induction has not been investigated in vivo and brivaracetam may decrease plasma concentrations of medicinal products metabolised by CYP2B6 (e.g. efavirenz).
Indukcija enzima CYP2B6 nije se ispitivala in vivo i brivaracetam može smanjiti plazmatske koncentracije lijekova metaboliziranih s enzimom CYP2B6 (npr. efavirenza).
CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite.
CYP2C19 je uključen u nastanak aktivnog metabolita i intermedijarnog metabolita, 2- oksoklopidogrela.
CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite.
CYP2C19 je uključen u nastanak aktivnog metabolita i intermedijarnog metabolita, 2-okso- klopidogrela.
CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite.
CYP2C19 je uključen u nastanak aktivnog metabolita i intermedijernog metabolita 2-okso- klopidogrela.
CYP2C19) in the metabolism of tasimelteon is unknown.
CYP2C19) u metabolizmu tazimelteona nije poznata.
CYP2C19, CYP2D6, CYP2E1, and CYP3A4.
CYP2D6, CYP2E1 i CYP3A4.
CYP2C8
lijeka
CYP2C8 and CYP2D6 at clinically relevant concentrations.
i CYP2D6 pri klinički značajnim koncentracijama.
CYP2C9 and CYP2C19 induction
Lamotrigin i Valproat
CYP2C9 poor metabolizers
Slabi metabolizatori CYP2C9
CYP2C9 substrates (e.g.
Supstrati CYP2C9 (npr.
CYP2C9 substrates (e.g.R-warfarin)
Supstrati izoenzima CYP2C9 (npr.
CYP2C9, CYP2C19, UGT1A1 and MRP2.
CYP2C9, CYP2C19, UGT1A1 i MRP2.
CYP2D6 genetic polymorphism has minimal impact on the mean plasma exposure to mirabegron (see section 5.2).
Genetski polimorfizam CYP2D6 je imao minimalan učinak na srednju vrijednost ekspozicije plazme mirabegrona (vidjeti dio 5.2).
CYP2D6 inhibitors used simultaneously with CYP3A inhibitors In intermediate (IMs) and extensive metabolisers (EMs):
Inhibitori CYP2D6 u istovremenoj primjeni s inhibitorima CYP3A Kod intermedijarnih (IM) i ekstenzivnih metabolizatora (EM):
CYP2D6 phenotype
Fenotip CYP2D6
CYP2D6 substrates (e.g. desipramine, metoprolol and dextromethorphan) are not expected to require dose adjustments.
Za supstrate za CYP2D6 (npr. dezipramin, metoprolol i dekstrometorfan) ne očekuje se potreba prilagodbe doze.
CYP2D6 substrates with a narrow therapeutic window such as metoprolol.
CYP2D6 s uskom terapijskom širinom, poput metoprolola.
CYP2D6 ultra-rapid metabolisers (URMs) and indeterminate metabolisers
Ultrabrzi metabolizatori (UBM) i neodređeni metabolizatori CYP2D6
CYP2E1 was slightly inhibited (50% inhibitory concentration [IC50] of approximately 20 µM [11 µg/mL]), although this is not expected to result in any clinically meaningful interactions.
CYP2E1 je bio malo inhibiran (50% inhibicijske koncentracije [IC50] od približno 20 µM [11 µg/ml]), iako se ne očekuje da će to rezultirati bilo kakvom klinički značajnom interakcijom.
CYP3A and organic anion
telaprevir inibira CYP3A i
CYP3A by
CYP3A
CYP3A by
izlučivanjem putem
CYP3A by LUM
CYP3A
CYP3A by LUM immunosuppressants, which may reduce the efficacy of these immunosuppressants.
Lumakaftor/ivakaftor će smanjiti izloženost ovim imunosupresivima, što može oslabiti njihovu djelotvornost.
CYP3A by St. John’s
CYP3A gospinom
CYP3A by these
CYP3A ovim
CYP3A by these
lumakaftora/ivakaftora s ovim
CYP3A inducers that are contraindicated include rifampicin, St John’s wort and lopinavir.
Kontrainidicirani CYP3A induktori uključuju npr. rifampicin, gospinu travu i lopinavir.
CYP3A inhibition by atazanavir
inhibicija CYP3A koju uzrokuju
CYP3A inhibition)
uključujući inhibiciju CYP3A)
CYP3A substrate)
CYP3A)
CYP3A substrates evaluated in drug interaction studies which may require dose adjustment and/or clinical monitoring include (see Table 2) cyclosporine, tacrolimus, amlodipine, rilpivirine and alprazolam.
CYP3A supstrati koji su ocijenjeni u ispitivanjima interakcija lijekova za koje je možda potrebna prilagodba doze i/ili kliničko praćenje uključuju (vidjeti Tablicu 2) ciklosporin, takrolimus, amlodipin, rilpivirin i alprazolam.
CYP3A/2C19 by
CYP3A/2C19
CYP3A4
da efavirenz
CYP3A4
doza
CYP3A4 (e.g., sufentanil) should be considered.
Statini (npr. lovastatin)
CYP3A4 a net inhibitory effect on
inhibitorni učinak na maravirok.
CYP3A4 and CYP2B6 substrates
Supstrati CYP3A4 i CYP2B6
CYP3A4 and have a narrow
CYP3A4 i imaju uzak terapijski
CYP3A4 and PgP inducers decreasing everolimus concentrations
CYP3A4 i PgP induktori snižavaju koncentraciju everolimusa
CYP3A4 and therefore affect drugs
CYP3A4 te stoga utječe na lijekove
CYP3A4 by FPV/RTV)
(Blaga indukcija CYP3A4
CYP3A4 inducer medicines (such as antibiotic medicine - rifampicin, and anticonvulsant medicines - carbamazepine, phenobarbital, phenytoin)
lijekove za kontrolu začeća - drospirenon lijekove koji su induktori enzima CYP3A4 (kao što su antibiotici - rifampicin i lijekovi protiv napadaja - karbamazepin, fenobarbital, fenitoin)
CYP3A4 inducers (anticonvulsant agents [e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone], rifampicin, Hypericum perforatum [St. John’s wort])
CYP3A4 induktori (antikonvulzivni lijekovi [npr. karbamazepin, fenobarbital, fenitoin, fosfenitoin, primidon], rifampicin, Hypericum perforatum [gospina trava])
CYP3A4 inducers (anticonvulsant agents [e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone], rifampicin, Hypericum perforatum)
CYP3A4 induktori (antikonvulzivni lijekovi [npr. karbamazepin, fenobarbital, fenitoin, fosfenitoin, primidon], rifampicin, Hypericum perforatum)
CYP3A4 inducers (such as, but not limited to, avasimibe, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin (rifampicin), St.John’s wort (Hypericum perforatum))
CYP3A4 induktori (kao što su, između ostalih, avasimib, karbamazepin, fenobarbital, fenitoin, rifabutin, rifampin (rifampicin), gospina trava (Hypericum perforatum))
CYP3A4 inducers and inhibitors
Induktori i inhibitori CYP3A4
CYP3A4 inducers potentially leading to decreased tacrolimus blood levels
Induktori CYP3A4 koji mogu dovesti do smanjenja koncentracije takrolimusa u krvi
CYP3A4 inducers: Concomitant use of CYP3A4 inducers with buprenorphine may decrease buprenorphine plasma concentrations, potentially resulting in sub-optimal treatment of opioid dependence with buprenorphine.
induktorima CYP3A4: Istodobna primjena induktora CYP3A4 s buprenorfinom može sniziti koncentraciju buprenorfina u plazmi te potencijalno rezultirati suboptimalnim liječenjem ovisnosti o opioidima buprenorfinom.
CYP3A4 inducers: CYP3A4 inducers (e.g. rifampicin, barbiturates, phenytoin, Hypericum perforatum [St John’s Wort]) may decrease ivabradine exposure and activity.
CYP3A4 induktori: CYP3A4 induktori (npr. rifampicin, barbiturati, fenitoin, Hypericum perforatum [Gospina trava]) mogu smanjiti koncentraciju i djelovanje ivabradina.
CYP3A4 induction by nevirapine
indukcija CYP3A4 koju uzrokuje
CYP3A4 induction by rifampicin
Rifampicin inducira CYP3A4.
CYP3A4 induction was observed in a clinical trial when a single dose of midazolam was co- administered after repeat dosing with vemurafenib for 15 days.
Kad je, u kliničkom ispitivanju, nakon primjene višekratnih doza vemurafeniba tijekom 15 dana istodobno primijenjena jednokratna doza midazolama, opažena je indukcija CYP3A4.
CYP3A4 inhibition
Inhibicija CYP3A4
CYP3A4 inhibition by atazanavir
inhibicija CYP3A4 koju uzrokuju
CYP3A4 inhibition.
CYP3A4.
CYP3A4 inhibition.
enzima CYP3A4.
CYP3A4 inhibition: Based upon clinical data, known specific and non-specific CYP3A4 inhibitors appear to have no clinically relevant effect on zonisamide pharmacokinetic exposure parameters.
Inhibicija CYP3A4: na temelju kliničkih podataka, poznati specifični i nespecifični inhibitori CYP3A4 čini se da nemaju klinički važan učinak na farmakokinetičke parametre izloženosti zonisamidu.
CYP3A4 inhibition: Based upon clinical data, known specific and non-specific CYP3A4 inhibitors appear to have no clinically relevant effect on zonisamide pharmacokinetic exposure parameters.
Inhibicija CYP3A4: na temelju kliničkih podataka, poznati specifični i nespecifični inhibitori CYP3A4 čini se da nemaju klinički značajan učinak na farmakokinetičke parametre izloženosti zonisamidu.
CYP3A4 inhibitors (i.e. ketoconazole, itraconazole, ritonavir)
CYP3A4 inhibitori (tj. ketokonazol, itrakonazol, ritonavir)
CYP3A4 inhibitors and CYP2C9 inhibitors
Inhibitori CYP3A4 i inhibitori CYP2C9
CYP3A4 inhibitors like clarithromycin, telithromycin and nefazodone) are expected to have an effect in between that of ritonavir and CYP3A4 inhibitors like saquinavir or erythromycin), a seven-fold increase in exposure is assumed.
Očekuje se da će učinak inhibitora CYP3A4 kao što su klaritromicin, telitromicin i nefazodon biti između učinka ritonavira i učinka inhibitora CYP3A4 poput sakvinavira ili eritromicina; pretpostavlja se da će izloženost sedmerostruko porasti.
CYP3A4 inhibitors potentially leading to increased tacrolimus blood levels
Inhibitori CYP3A4 koji mogu dovesti do povećanja koncentracije takrolimusa u krvi
CYP3A4 inhibitors potentially leading to increased tacrolimus blood levels
Inhibitori CYP3A4 koji mogu dovesti do povišenja razina takrolimusa u krvi
CYP3A4 inhibitors such as ketoconazole, itraconazole, or fluconazole (used for treatment of fungal infections),
CYP3A4 inhibitori, poput ketokonazola, itrakonazola ili flukonazola (za liječenje gljivičnih infekcija)
CYP3A4 inhibitors such as ketoconazole, itraconazole, or fluconazole (used for treatment of fungal infections),
CYP3A4 inhibitori, poput ketokonazola, itrakonazola ili flukonazola (za liječenje gljivičnih infekcija),
CYP3A4 inhibitors, chloroquine, hydroxychloroquine, fibric acid derivatives, penicillamine, zidovudine, niacin and HMG-CoA reductase inhibitors) (see section 4.5).
CYP3A4 inhibitori, klorokin, hidroksiklorokin, derivati fibratne kiseline, penicilamin, zidovudin, niacin i inhibitori HMG-CoA reduktaze) (vidjeti dio 4.5).
CYP3A4 inhibitors: an interaction study of buprenorphine with ketoconazole (a potent inhibitor of CYP3A4) resulted in increased Cmax and AUC (area under the curve) of buprenorphine (approximately 50 % and 70 % respectively) and, to a lesser extent, of norbuprenorphine.
inhibitorima CYP3A4: ispitivanje interakcija buprenorfina s ketokonazolom (jaki inhibitor CYP3A4) rezultiralo je povećanjem Cmax (za 50 %) i AUC (područje ispod krivulje) (za 70 %) buprenorfina, i u manjoj mjeri, norbuprenorfina.
CYP3A4 mediated metabolism may be a minor pathway.
Metabolizam posredovan s CYP3A4 može biti manje važan put.
CYP3A4 substrates known to have a narrow therapeutic index (e.g. astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil or ergot alkaloids (ergotamine, dihydroergotamine)) should therefore be administered with caution in patients receiving lenvatinib.
Stoga se supstrati CYP3A4 za koje se zna da imaju uzak terapijski indeks (npr. astemizol, terfenadin, cisaprid, pimozid, kinidin, bepridil ili ergot alkaloidi (ergotamin, dihidroergotamin)) trebaju primjenjivati s oprezom u bolesnika koji primaju lenvatinib.
CYP3A4 substrates with a narrow therapeutic window (e.g. cyclosporine, pimozide, tacrolimus, sirolimus, ergotamine, diergotamine, fentanyl, alfentanil, terfenadine, bortezomib, docetaxel, quinidine) or warfarin and other coumarin derivatives (see section 4.5).
Potreban je oprez kada se imatinib uzima s inhibitorima proteaze, azolnim antimikoticima, određenim makrolidima (vidjeti dio 4.5), CYP3A4 supstratima s uskim terapijskim prozorom (npr. ciklosporin, pimozid, takrolimus, sirolimus, ergotamin, diergotamin, fentanil, alfentanil, terfenadin, bortezomib, docetaksel, kinidin) ili varfarinom i drugim derivatima kumarina (vidjeti dio 4.5).
CYP3A4 was the major CYP isoenzyme involved in vitro in the metabolism of bedaquiline and the formation of the N-monodesmethyl metabolite (M2).
In vitro, CYP3A4 je bio glavni CYP izoenzim uključen u metabolizam bedakilina i nastanak N- monodezmetil metabolita (M2).
CYP3A4 were not involved in the metabolism of cysteamine bitartrate under the experimental conditions.
nisu uključeni u metabolizam cisteamin bitartrata u eksperimentalnim uvjetima.
CYP3A4, P-gp, BCRP inducers
Induktori CYP3A4, P-gp, BCRP-a
CYP3A4, P-gp, BCRP inhibitors
Inhibitori CYP3A4-a, P-gpa, BCRP-a
CYP3A4, such as carbamazepine,
poput karbamazepina, fenobarbitala i
CYP3A4-inducing
induktora CYP3A4